Vestar Inc. news

VSTR hopes to have MiKasome in the clinic to treat tuberculosis within three months; to move VincaXome and CycloXome into cancer trials by late 1993 or early 1994; and to start trials of AMP-53 in 12 to 18 months.

VSTR President and CEO Roger Crossley told BioCentury his strategy is to move multiple products through the clinic, keeping those that work and making decisions quickly about those that don't. ...